ArticleJournal of molecular medicine (Berlin, Germany)2015
Curcumin nanoparticles inhibit corneal neovascularization.
Article in Journal of molecular medicine (Berlin, Germany), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 49 citations in OpenAlex.
- Cascade-targeted intervention of the NLRP3 inflammasome and downstream angiogenesis by curcumin nanoparticles for ocular neovascularization therapy.Clinical and translational medicine · 2026Article
- Managing dry eye disease - a review of selected traditional Chinese medicine and some of their metabolites focusing on molecular mechanisms and signaling pathways.Frontiers in pharmacology · 2026Review
- Astaxanthin ameliorates benzalkonium chloride-induced dry eye disease through suppressing inflammation and oxidative stress via Keap1-Nrf2/HO-1 signaling pathways.Animal models and experimental medicine · 2025Article
- Novel ophthalmic hyaluronic acid-hydrogel with curcumin nanoparticles for enhanced healing of ulcerative keratitis in rabbit model.Scientific reports · 2024Article
- Next-generation nanomaterials: advancing ocular anti-inflammatory drug therapy.Journal of nanobiotechnology · 2023Review
- The Pathomechanism, Antioxidant Biomarkers, and Treatment of Oxidative Stress-Related Eye Diseases.International journal of molecular sciences · 2022Review
- An Update on Novel Ocular Nanosystems with Possible Benefits in the Treatment of Corneal Neovascularization.International journal of nanomedicine · 2022Review
- Harnessing the tunable cavity of nanoceria for enhancing Y-27632-mediated alleviation of ocular hypertension.Theranostics · 2021Article
- Curcumin Metabolite Tetrahydrocurcumin in the Treatment of Eye Diseases.International journal of molecular sciences · 2020Review
- Obstacles against the Marketing of Curcumin as a Drug.International journal of molecular sciences · 2020Review
- Pharmacological Potential of Small Molecules for Treating Corneal Neovascularization.Molecules (Basel, Switzerland) · 2020Review
- Article
- Review
- Therapeutic potential of curcumin in eye diseases.Central-European journal of immunology · 2019Review
- Effects of Curcumin on Vessel Formation Insight into the Pro- and Antiangiogenesis of Curcumin.Evidence-based complementary and alternative medicine : eCAM · 2019Review
- Nanotechnology: from In Vivo Imaging System to Controlled Drug Delivery.Nanoscale research letters · 2017Review
- Preparation of arginine-glycine-aspartic acid-modified biopolymeric nanoparticles containing epigalloccatechin-3-gallate for targeting vascular endothelial cells to inhibit corneal neovascularization.International journal of nanomedicine · 2017Article
- Suppression of corneal neovascularization by curcuminInternational journal of ophthalmology · 2017Article
- Curcumin, A Potential Therapeutic Candidate for Anterior Segment Eye Diseases: A Review.Frontiers in pharmacology · 2017Review
- Therapeutic Applications of Curcumin Nanoformulations.The AAPS journal · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
unlabelledCorneal neovascularization is a leading cause for compromised vision. Therapeutic prevention of corneal neovascularization is a major clinical challenge, and there is a compelling need to seek effective and safe therapy for this pathology. This study is aimed to evaluate curcumin nanoparticle for prevention of corneal neovascularization. MePEG-PCL nanoparticles were successfully prepared and characterized. The nanoparticle of curcumin has shown increased efficiency in preventing angiogenic sprouting in vitro. Topical delivery of curcumin nanoparticle in the eye showed enhanced retention of curcumin in the cornea, and significant improvement in prevention of corneal neovascularization over free curcumin as graded clinically and by histopathology; suppression in the expression of VEGF, inflammatory cytokines, and MMP was evidenced in the treated cornea. Curcumin inhibited NFκB in LPS-induced corneal cells. Histopathology and scanning electron microscopy showed absence of any adverse change in the corneal structure following application of curcumin nanoparticle. Therefore, we conclude that curcumin nanoparticle can be a potential candidate for prevention of corneal neovascularization. KEY MESSAGE: • Curcumin nanoparticles show enhanced retention of curcumin in the cornea. • Curcumin NPs suppress the expression of VEGF, inflammatory cytokines, and MMP. • Curcumin NPs prevent corneal neovascularization by suppressing the NFκB pathway. • Curcumin NPs may be a promising candidate for prevention of corneal neovascularization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.